Orforglipron Maintains Weight Loss After Injectable Therapy
Key Takeaways
- Greater maintenance of prior weight loss was observed with once-daily oral orforglipron than placebo in both prior-injectable cohorts.
- All key secondary endpoints were met, including maintenance of at least 80% of the earlier weight reduction.
- Gastrointestinal events were the most common adverse events, were mostly mild to moderate, and led to discontinuation in a minority of orforglipron-treated participants without a reported liver safety signal.
ATTAIN-MAINTAIN consisted of two phase 3b randomized, double-blind, placebo-controlled cohorts at 29 U.S. sites, analyzed separately after completion of SURMOUNT-5. Eligible participants were adults with obesity or body mass index at least 27 kg/m2 with obesity-related complications, without diabetes, and with at least 5% body weight reduction at week 72. Cohort 1 randomized 125 participants to orforglipron and 80 to placebo, while cohort 2 randomized 105 to orforglipron and 66 to placebo. The first dose was ideally given within 14 days of the last SURMOUNT-5 dose, then escalated from 12 mg daily every 4 weeks to 36 mg or the maximum tolerated dose during a 52-week treatment period with 2-week safety follow-up. Placebo participants could begin rescue orforglipron at week 24 after regaining at least 50% of prior weight loss, and the primary endpoint was percent maintenance of body weight reduction among plateau participants.
In cohort 1, participants who reached a body-weight plateau maintained 74.7% of prior weight loss with orforglipron and 49.2% with placebo, a treatment difference of 25.5 percentage points. The 95% confidence interval was 14.5 to 36.5, and the between-group difference met statistical significance with P<0.001. In cohort 2, the corresponding values were 79.3% and 37.6%, yielding a 41.7 percentage point difference with a 95% confidence interval of 24.4 to 59.0 and P<0.001. Maintenance of at least 80% of prior weight reduction occurred in 43.7% versus 16.4% in cohort 1 and 55.0% versus 6.9% in cohort 2, with both comparisons meeting P<0.001. All key secondary endpoints were met, and waist circumference plus selected cardiometabolic measures remained improved after the switch.
The most common adverse events were gastrointestinal, including nausea, constipation, vomiting, and diarrhea, and these events were mostly mild to moderate. During the first 4 weeks after transition, gastrointestinal events occurred in 10.5% of participants in cohort 1 and 9.5% in cohort 2, with no dose de-escalations after direct transition to 12 mg. Discontinuations because of adverse events ranged from 4.8% to 7.3% across the orforglipron groups. Serious adverse events were uncommon, including one adjudicated mild pancreatitis case in cohort 1 and one death in cohort 2 that investigators did not consider treatment related. Alanine and aspartate aminotransferase elevations occurred in small numbers, and no liver safety signal was detected. Overall, the safety profile was dominated by gastrointestinal events rather than a new major signal.
The trial did not include a comparator arm that continued injectable obesity medication, so it does not address whether switching to oral therapy matches continued tirzepatide or semaglutide. Other limitations included the 1-year duration, the predominantly white population enrolled only in the United States, and cardiometabolic analyses that were exploratory or planned for fuller future reporting. Across both cohorts, adults with prior injectable incretin-associated weight loss preserved more of that loss over 52 weeks with oral orforglipron than with placebo.
Frequently Asked Questions
What's the latest on GLP-1 receptor agonists for obesity and weight management?
ATTAIN-MAINTAIN is the first Phase 3 trial to test whether an oral GLP-1 receptor agonist can maintain weight reduction achieved with injectable incretins. Across two cohorts (n=376) of adults who completed 72 weeks of injectable tirzepatide or semaglutide in SURMOUNT-5, switching to once-daily oral orforglipron preserved 74.7% (vs 49.2% on placebo; +25.5 percentage points; P<0.001) and 79.3% (vs 37.6%; +41.7 percentage points; P<0.001) of prior weight loss among plateau participants. Maintenance of at least 80% of prior weight reduction occurred in 43.7% vs 16.4% (cohort 1) and 55.0% vs 6.9% (cohort 2); both P<0.001. Waist circumference and selected cardiometabolic measures remained improved after the switch.
Where can I find CME on GLP-1 prescribing for non-diabetic obesity?
The Advances in Obesity Management Learning Center on ReachMD aggregates accredited education on GLP-1 receptor agonist prescribing in adults with obesity or overweight without diabetes, including patient selection, dose escalation, transition strategies between injectable and oral therapies (as in ATTAIN-MAINTAIN), and management of GI adverse events: Advances in Obesity Management. Specialty endocrinology content is at Endocrinology CME. Both are free after a no-cost ReachMD registration.
Where can I find free CME on hot clinical topics like obesity drugs and GLP-1s?
ReachMD's Advances in Obesity Management Learning Center and Endocrinology CME hub host free accredited education on the active obesity drug pipeline, including orforglipron (oral non-peptide GLP-1 RA — FDA-approved under CNPV; maintenance therapy in ATTAIN-MAINTAIN), semaglutide 7.2 mg (STEP UP), tirzepatide (SURMOUNT series, SURPASS-CVOT), and survodutide (SYNCHRONIZE-1). Modules are updated as trials report, and recent CME programs include head-to-head injectable comparisons, maintenance-of-effect after injectable therapy, and primary-care prescribing pathways: Advances in Obesity Management and Endocrinology CME.
What were the safety findings for orforglipron in ATTAIN-MAINTAIN?
The most common adverse events were gastrointestinal (nausea, constipation, vomiting, diarrhea), mostly mild to moderate. During the first 4 weeks after transition from injectable therapy, GI events occurred in 10.5% (cohort 1) and 9.5% (cohort 2) of orforglipron participants, with no dose de-escalations after direct transition to the 12 mg starting dose. Discontinuations due to adverse events ranged from 4.8% to 7.3% across orforglipron groups. Serious adverse events were uncommon — one adjudicated mild pancreatitis case (cohort 1) and one death (cohort 2) judged not treatment-related. ALT and AST elevations occurred in small numbers; no liver safety signal was detected.
Who was studied and what does ATTAIN-MAINTAIN not yet answer?
ATTAIN-MAINTAIN enrolled 376 U.S. adults across 29 sites who had completed 72 weeks of injectable tirzepatide (cohort 1: 125 to orforglipron, 80 to placebo) or semaglutide (cohort 2: 105 to orforglipron, 66 to placebo) in SURMOUNT-5, had obesity or BMI ≥27 kg/m² with obesity-related complications, were without diabetes, and had achieved at least 5% weight reduction at SURMOUNT-5 week 72. The trial does not include a comparator arm continuing injectable therapy, so it does not address whether switching to oral orforglipron matches continued tirzepatide or semaglutide; the 52-week duration, predominantly white U.S. population, and exploratory cardiometabolic endpoints are additional limits.